Secretome Therapeutics Raises $30M in Series A Funding

The Series A funding will support operations and help advance Secretome Therapeutics’ pipeline, including STM-01, a therapy derived from neonatal cardiac progenitor cells that is being developed for Duchenne muscular dystrophy-related cardiomyopathy and other rare heart conditions linked to neuromuscular diseases.

The company plans to use the funding to move STM-01 into Phase 2 and Phase 3 development for Duchenne muscular dystrophy, a disease with limited treatment options that can slow progression.

In connection with the financing, David Lubner has joined the Board of Directors of Secretome Therapeutics, while Charles Edwards will step down from the board.

Mr. Lubner has more than 25 years of experience in the biotechnology industry as both an executive and board member. He previously served as Executive Vice President and Chief Financial Officer of Ra Pharmaceuticals until its acquisition by UCB in 2020. Earlier in his career, he was CFO of Tetraphase Pharmaceuticals, PharMetrics, and ProScript.

He currently serves on the boards of Crescent Bio and Dyne Therapeutics, along with several private companies. He previously served on the boards of Arcellx, Nightstar Therapeutics and POINT Biopharma through their acquisitions by Gilead Sciences, Biogen and Eli Lilly and Company. He also served on the boards of Cargo Therapeutics and Vor Biopharma until August 2025.

Matthew Hammond, Partner at RA Capital Management, will also join Secretome Therapeutics as a Board Observer. The company also announced that Charles Edwards has stepped down from the Board of Directors. Secretome thanked Dr. Edwards for his contributions, guidance, and support during an important stage of the company’s growth.

“RA Capital’s investment represents an inflection point for Secretome, and a validation of our science, team, and clinical development strategy,” said Vinny Jindal, President, Chief Executive Officer and Co-founder of Secretome Therapeutics. “Moreover, with this financing, Secretome can develop STM-01 expeditiously as a potential gold standard therapy for patients and families affected by Duchenne muscular dystrophy. We are grateful for the deep financial, operational, and strategic expertise that David Lubner brings to our Board as Secretome enters its next major stage of growth. On behalf of the company, I also want to thank Dr. Charles Edwards for his long-standing support of our mission and team, and the many contributions he has made to Secretome.”

Read More:Fields Good Raises $1.8M in Pre-Seed Funding

“Secretome is emerging as a leading immunology and inflammation (I&I) company in the area of cardiac disease, and a leader in the development of progenitor cell-based therapeutics,” said Matthew Hammond, PhD, MBA, Partner at RA Capital Management, “We believe in STM-01 will be a disease-modifying and best-in-class cellular therapy for patients with DMD, and the first of a broader pipeline of nCPC-based therapies from Secretome.”

About Secretome Therapeutics

Founded in 2018 by Vinny Jindal, Secretome Therapeutics is a clinical-stage biotech company based in Plano, Texas, developing therapies made from neonatal cardiac progenitor cells. Its lead therapy candidate, STM-01, is designed to reduce inflammation, and fibrosis while improving heart function in patients with Duchenne muscular dystrophy-related cardiomyopathy, dilated cardiomyopathy and heart failure with preserved ejection fraction.

Read More:Patron Points Receives Investment From Straylight Capital